Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Bret Bostwick cites ApoE as a model: E4 homozygotes face 10 to 20 times higher Alzheimer's risk, E2 carriers are protected, and rare ApoE mutations can prevent disease in people destined for early onset. That rare protective evidence lets investors bookend confidence before clinical trials.

Related Insights

Instead of only seeking disease-causing genes, Regeneron's primary strategy is to find rare protective mutations in individuals they call "superhumans." These people, naturally protected from diseases like heart attacks, provide a validated blueprint for new drugs. The company has already found over 50 such protective factors.

Human genetics doesn't just provide a drug target; it often specifies the therapeutic approach required. Discovering a protective loss-of-function mutation immediately tells researchers to develop an inhibitor (like an antibody or siRNA), accelerating the path from target discovery to molecule design.

Instead of traditional methods, Regeneron sequences millions of people to find "superhumans"—those with rare genetic mutations that protect them from diseases. By studying these individuals, they identify high-confidence drug targets that mimic these natural protections, aiming for a higher probability of success in development.

Regeneron systematically expands the market for its drugs through "indication expansion." By identifying people in its database with a natural loss-of-function variant for a drug's target, they can scan thousands of diseases to see what other conditions these people are protected from, revealing new therapeutic opportunities.

The primary bottleneck in drug development isn't creating therapies but identifying the right targets. Regeneron built its massive genetics database to find rare, protective genetic mutations in humans, effectively de-risking the target identification process and aiming to improve the industry's low success rate.

The APOE4 gene significantly increases Alzheimer's risk, but its effect is not equal between sexes. A woman with one copy of the gene has double the risk of her male counterpart, elevating her total risk six-fold. Two copies increase a woman's risk by a staggering 15-fold.

Step Pharma's confidence in their drug's clean safety profile originated from studying a human population with a natural mutation in the CTPS1 gene. This real-world genetic data de-risked their therapeutic approach from the outset, guiding development towards a highly selective and safe inhibitor.

The drug's target, the inhibin E gene, was identified from large-scale human genetic studies. Individuals with a natural loss-of-function variant in this gene exhibit a healthier cardiometabolic profile, providing strong human validation for the therapeutic approach before clinical trials even began, increasing the likelihood of success.

Previously, genetic validation was a perfunctory, yes/no question asked late in the drug discovery process. Now, sophisticated VCs and pharma companies demand this evidence much earlier, recognizing its critical role in predicting clinical success. It has become a prerequisite for investment rather than a final confirmation step.

The development of PCSK9 inhibitors, a powerful class of cholesterol-lowering drugs, originated not from studying disease but from studying healthy people with a genetic mutation causing exceptionally low LDL. This highlights the value of investigating positive outliers in human biology.